PedAM
Pediatric Disease Annotations & Medicines
| Disease | proteinuria |
| Phenotype | C0011860|type 2 diabetes |
| Sentences | 19 |
| PubMedID- 22218118 | Angiotensin receptor blocker and n-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus. |
| PubMedID- 24628963 | It has been reported to increase the risk of cardiovascular diseases and mortality in such patients [14] and to promote proteinuria in patients with type 2 diabetes [15]. |
| PubMedID- 20168990 | A single nucleotide polymorphism within the acetyl-coenzyme a carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes. |
| PubMedID- 24174939 | As far as our investigation there is no clinical trial that has studied the effect of 25(oh) d on decreasing the proteinuria in patients with type 2 diabetes. |
| PubMedID- 23083001 | And there is a need to explore the association between egfr and mortality by stratifying proteinuria status in patients with type 2 diabetes. |
| PubMedID- 20617081 | It has also been reported that hyperhomocysteinemia precedes the development of overt proteinuria in patients with type 2 diabetes [13]. |
| PubMedID- 25893098 | Monitoring for proteinuria in patients with type 2 diabetes mellitus. |
| PubMedID- 26089878 | In addition, omega-3 fa could slow the progression of proteinuria in patients with type 2 diabetes, but the study in question included patients who were not controlling their bp [4]. |
| PubMedID- 20536492 | The objective of this study was to further investigate the dose-response effect of tobacco exposure on proteinuria in males with type 2 diabetes. |
| PubMedID- 23714217 | Methods: eighty-four type 2 diabetes patients with overt proteinuria and biopsy-confirmed diabetic nephropathy were enrolled. |
| PubMedID- 24391440 | A pilot study104 indicated that oral sdx at 200 mg daily was more often successful, although not significantly, than placebo in inducing at least 50% reduction of proteinuria in patients with type 2 diabetes treated with maximal allowed doses of ace inhibitors or arbs. |
| PubMedID- 20345850 | These include the recent avoid trial [26] in which aliskiren reduced proteinuria in patients with hypertension, type 2 diabetes and diabetic nephropathy. |
| PubMedID- 23169362 | The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. |
| PubMedID- 21247498 | We substantiate prievous findings and extend the association beyond type 1 diabetes, demonstrating a role for glut1 enh2 and proteinuria among those with type 2 diabetes. |
| PubMedID- 26109389 | Selective vitamin d receptor activator paricalcitol effectively reduce proteinuria in patients with type 2 diabetes through inhibition of the renin-angiotensin-aldosterone system (raas) [12]. |
| PubMedID- 19889469 | Diabetic nephropathy remission and regression team trial in japan (dnett-japan) is an open, randomized controlled trial to evaluate the efficacy of renal protection of multifactorial intensive therapy in type 2 diabetes patients with overt proteinuria (urinary albumin-to-creatinine ratio > or =300 mg/g creatinine). |
| PubMedID- 24357461 | Of note, single nucleotide polymorphisms in acetyl-coa carboxylase β gene, which plays an important role in the regulation of fatty acid metabolism, exhibit a potent association with proteinuria in patients with type 2 diabetes [6, 7]. |
| PubMedID- 23209764 | The selective vitamin d receptor (vdr) activator, paricalcitol, effectively reduces proteinuria in patients with type 2 diabetes mellitus (t2dm) who have been treated with raas inhibitors [6]. |
| PubMedID- 26169541 | It was reported to slow the progression of renal injury in a rat model of type 2 diabetes with preexisting proteinuria and renal disease (kojima et al. |
Page: 1